The RTS,S/AS01 (Mosquirix) vaccine is the most advanced malaria vaccine to date. It is a pre-erythrocytic vaccine that targets the circumsporozoite protein (CSP) of Plasmodium falciparum. Clinical trials have shown that it provides partial protection against malaria in young children. The World Health Organization (WHO) has recommended its pilot implementation in selected regions.
